← All trials
NCT05411744
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2022
- Primary completion
- Jun 30, 2023
- Completion date
- Jun 30, 2025
- First posted
- Jun 9, 2022
- Last posted
- Jun 9, 2022
- Enrollment
- 25
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Rutgers UniversityLead sponsor
- Rutgers UniversityOverall official - principal investigator
- Rutgers UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.